Targeted inhibition of VEGF receptor 2: an update on ramucirumab

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

(2012) J H Yi et al.   BRITISH JOURNAL OF CANCER

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

(2012) Jung Hun Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy

(2012) Weijing Sun   Journal of Hematology & Oncology

Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs

(2012) E.-M. E. Hedlund et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Basic and Therapeutic Aspects of Angiogenesis

(2011) Michael Potente et al.   CELL

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

(2011) Peter C. Thuss-Patience et al.   EUROPEAN JOURNAL OF CANCER

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy

(2011) J. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies

(2011) Matthew C. Franklin et al.   STRUCTURE

Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

(2011) Jennifer Spratlin   Current Oncology Reports

Structural determinants of vascular endothelial growth factor-D receptor binding and specificity

(2010) V.-M. Leppanen et al.   BLOOD

PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth

(2010) Carlos Bais et al.   CELL

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203

(2010) Weijing Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis

(2010) Imke Albrecht et al.   PLoS One

An overview of small-molecule inhibitors of VEGFR signaling

(2009) S. Percy Ivy et al.   Nature Reviews Clinical Oncology

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

(2008) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE